Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms by Site × HuMax-IL8 × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Melanoma 2 Neoplasms by Site 1 Neoplasms by Histologic Type 1

Interventions

cobimetinib 2 spartalizumab 1 pembrolizumab 1 osimertinib 1 glutathione pegylated liposomal doxorubicin 1 alectinib 1 Vemurafenib 1 Trastuzumab 1 Taxes 1 Radiosurgery 1 Pemetrexed 1 Paclitaxel 1 Nivolumab 1 HuMax-IL8 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

University of Pittsburgh

Phase 1 Recruiting

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon ⚡